<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Arbutus Biopharma Corporation

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Arbutus Biopharma Corporation

    Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      William H. Collier
    • FOUNDED
      1992
    • EMPLOYEES
      51-100
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Oncolytics Biotech Inc.

    Oncolytics Biotech Inc.

    Oncolytics is focused on obtaining regulatory approval for pelareorep for metastat...

    Oncolytics is focused on obtaining regulatory a...

    Filing Type:    PU
    Athenex, Inc.

    Athenex, Inc.

    Athenex is a global oncology focused biopharmaceutical company dedicated to the di...

    Athenex is a global oncology focused biopharmac...

    Filing Type:    PU
    United-Guardian, Inc.

    United-Guardian, Inc.

    United-Guardian, Inc. ("United") is a diversified company that conducts research, ...

    United-Guardian, Inc. ("United") is a diversifi...

    Filing Type:    PU
    SIGA Technologies Inc.

    SIGA Technologies Inc.

    SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focus...

    SIGA Technologies, Inc. is a public, commercial...

    Filing Type:    PU
    Trevi Therapeutics, Inc.

    Trevi Therapeutics, Inc.

    We are developing nalbuphine ER to treat serious neurologically mediated condition...

    We are developing nalbuphine ER to treat seriou...

    Filing Type:    PU
    Sierra Oncology, Inc.

    Sierra Oncology, Inc.

    Sierra Oncology is a clinical stage drug development company advancing targeted th...

    Sierra Oncology is a clinical stage drug develo...

    Filing Type:    PU
    Assembly Biosciences, Inc.

    Assembly Biosciences, Inc.

    Assembly Biosciences is advancing a new class of oral therapeutics for the treatme...

    Assembly Biosciences is advancing a new class o...

    Filing Type:    PU
    VBI Vaccines, Inc.

    VBI Vaccines, Inc.

    VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company d...

    VBI Vaccines Inc. (Nasdaq: VBIV) is a commercia...

    Filing Type:    PU
    Spring Bank Pharmaceuticals, Inc.

    Spring Bank Pharmaceuticals, Inc.

    Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...

    Spring Bank is a clinical-stage biopharmaceutic...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.